Day: June 30, 2022

Agreement provides multiple benefits including Corporate governance enhancements and operating cost savings VICTOR, N.Y., June 30, 2022 (GLOBE NEWSWIRE) — Constellation Brands (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that following the recommendation of a special committee comprised solely of independent directors, its Board of Directors has approved, and will recommend to shareholders for approval, a proposal to eliminate the company’s Class B common stock. The proposed transaction contemplates that each outstanding share of the company’s Class B common stock, including those owned by the Sands Family, will be converted into the right to receive one share of Class A common stock plus cash consideration in the amount of $64.64 per share of Class B common stock, or a total amount of $1.5 billion....

Marcia J. Avedon Photo Marcia J. Avedon, Ph.D., Acuity Brands, Inc. Board MemberAtlanta, June 30, 2022 (GLOBE NEWSWIRE) — ATLANTA, June 30, 2022 – Acuity Brands, Inc. (NYSE: AYI) (the “Company”) announced today that, effective June 29, 2022, the Board of Directors (the “Board”) approved an increase in the size of the Board from 10 to 11 members and elected Marcia J. Avedon, Ph.D. as an Independent Director. Dr. Avedon will serve on the Governance and Compensation and Management Development Committees. She will serve for a term that will expire at the Company’s next annual meeting of stockholders. Dr. Avedon most recently served as Executive Vice President, Chief Human Resources, Marketing and Communications Officer for Trane Technologies PLC, where she was responsible for all global human resource and reputation management strategies...

– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions – – Codiak has identified recommended Phase 2 dose for each program and plans to initiate Phase 2 studies for both candidates in the first quarter of 2023 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced...

SHANGHAI, China, June 30, 2022 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that its annual general meeting (the “AGM”) was held in Shanghai on June 30, 2022 and all the proposed resolutions set out in the notice of AGM were duly passed at the AGM. All necessary shareholders’ approval in respect of the Company’s proposed conversion to primary listing on the Hong Kong Stock Exchange (the “Proposed Conversion”) has been obtained at the AGM. From the date of this announcement until the effective date of the Proposed Conversion, which is expected to be October 3, 2022 (the “Effective Date”), the Company will continue to make the necessary arrangements to facilitate compliance with all applicable...

Dr. Chad Beyer will join as CEO on July 1, 2022 NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc (“Promentis”), as Chief Executive Officer of Kures, effective July 1, 2022. Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discovery teams and participated in the submission of more than 30 INDs and provided supporting data...

GRAND CAYMAN, Cayman Islands, June 30, 2022 (GLOBE NEWSWIRE) — Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”) (NYSE: NM), a global seaborne shipping and logistics company, announced that on June 30, 2022, the Company issued a notice of redemption with respect to an aggregate principal amount of $10,000,000 of its 11.25% Senior Secured Notes due 2022 (the “Notes”) at a redemption price equal to 100.00% of the aggregate principal amount thereof, plus accrued and unpaid interest to, but excluding, the redemption date of July 10, 2022. After this redemption, $80,000,000 in aggregate principal amount of Notes will remain outstanding. About Navios Holdings Navios Maritime Holdings Inc. (NYSE: NM) is a global seaborne shipping and logistics company focused on the transport and transshipment of dry bulk commodities...

SARASOTA, Fla., June 30, 2022 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (NYSE: ROP) announced today that it has updated its reportable segments. The three updated reportable segments are as follows:Application Software – Aderant, CBORD, CliniSys, Data Innovations, Deltek, IntelliTrans, PowerPlan, Strata, VertaforeNetwork Software – ConstructConnect, DAT, Foundry, iPipeline, iTradeNetwork, Loadlink, MHA, SHP, SoftWritersTechnology Enabled Products – CIVCO Medical Solutions, FMI, Inovonics, IPA, Neptune, Northern Digital, rf IDEAS, VerathonBeginning with the second quarter of 2022, the Company will report its quarterly and full year financial statements under the new segment structure with prior periods recast to reflect the change. Discontinued OperationsOn June 1, 2022, Roper announced an agreement to sell a majority...

We expect to release the H1 2022 results of DSV A/S in the morning of 26 July 2022. A webcast and conference call will be held at 11:00 am CEST. At the call, Group CEO Jens Bjørn Andersen, Group COO Jens Lund and Group CFO Michael Ebbe will present the H1 2022 Interim Financial Report. The presentation will be followed by a Q&A session. Date:                 26 July 2022 Time:                 11:00 am CEST To attend the conference call, you may do one of the following:       a.   Webcast Go to investor.dsv.com or https://dsv-events.eventcdn.net/events/h1-2022/       b.   Conference call Participant dial-in telephone numbers: DK: +45 78 15 01 07 UK: +44 (0) 333 300 9265 US: +1 646 722 4902 No prior registration is required to attend the teleconference, but we recommend participants to dial in 10 minutes prior to the scheduled start...

June 30th 2022   Photocat A/S (publ) today announces that it has completed a private placement of 600,000 new shares. Fonden Impagt A/S (410.391 new shares), Strategic Investments A/S (89.609 new shares) and Alumichem A/S (100.000 new shares). The placement will provide the company with SEK 8.4 million in new equity. The Board of Directors in Photocat A/S has utilized the authorization in the Company’s articles of association to complete a private placement without pre-emptive subscription right for the current shareholders. The issue of 500,000 new shares has been completed at a price of SEK 14.0 pr. share with a nominal amount of DKK 1 each. The price per share is equal to the publicly listed share price as per 17.00 29th June 2022 on First North, hence no discount has been offered to any of the investors. The placement will increase...